ArticleHuman vaccines & immunotherapeutics2026
Projected epidemiological impact of lowering the adult pneumococcal vaccination age from 60 to 50 years in Germany.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The epidemiological impact of lowering the vaccination age of German adults from 60 to 50 y was evaluated. An age- and serotype-specific dynamic transmission model was used to evaluate the impact of vaccination with either the 23-valent pneumococcal polysaccharide vaccine (PPSV23) or the 20-valent or 21-valent pneumococcal conjugate vaccines (PCV20 and V116, respectively) on pneumococcal disease incidence, including invasive pneumococcal disease (IPD) and inpatient and outpatient non-bacteremic pneumococcal pneumonia, over 10 y. The base case (PPSV23 of ages ≥60 at a 30% vaccination coverage rate [VCR]) was compared against four alternative scenarios with varying pneumococcal conjugate vaccines (PCV20 vs. V116) and starting age of universal vaccination (60 vs. 50) at the same VCR of 30%. Among all adults (ages ≥18) and compared to PPSV23 vaccination at ≥60 and a VCR of 30%, V116 led to 415,452 fewer cases of total pneumococcal disease, while vaccination at ≥50 led to 520,128 fewer cases; PCV20 with those same settings led to 230,950 and 325,694 fewer cases, respectively. When vaccinating ages ≥60 and ≥50 with V116, the projected incidence of IPD in year 10 declined to 22.1 and 20.5 per 100,000, respectively, and when using PCV20 in the same conditions, incidence was 23.0 and 21.8, respectively. In summary, lowering the adult vaccination age enhanced the epidemiological impact of pneumococcal vaccination in Germany, with V116 showing the greatest overall reductions in disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.